Pacira BioSciences (PCRX) Cash from Operations Growth (3y) (2013 - 2026)
Pacira BioSciences (PCRX) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Pacira BioSciences | 970.37 Mn | 719.34 Mn | 148.24 Mn | 9.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.72% |
| Mar 31, 2026 | 10.32% |
| Dec 31, 2025 | 1.29% |
| Sep 30, 2025 | 12.56% |
| Jun 30, 2025 | -26.14% |
| Mar 31, 2025 | 4.83% |
| Dec 31, 2024 | 12.59% |
| Sep 30, 2024 | -3.65% |
| Jun 30, 2024 | 20.89% |
| Mar 31, 2024 | 59.59% |
| Dec 31, 2023 | 0.65% |
| Sep 30, 2023 | 3.76% |
| Jun 30, 2023 | 68.50% |
| Mar 31, 2023 | 45.51% |
| Dec 31, 2022 | 17.51% |
| Sep 30, 2022 | 32.46% |
| Jun 30, 2022 | 9.40% |
| Mar 31, 2022 | 106.42% |
| Dec 31, 2021 | 3.04% |
| Sep 30, 2021 | 53.62% |